BioLok International Inc. (OTC) manufactures and distributes products that merge cell biology and technology to develop and market products for the dental implant and tissue regeneration markets
	Healthpoint Capital (HPC) is a private equity firm exclusively focused on the orthopedic and dental device businesses
	The Board of Directors of BioLok retained TM Capital to evaluate HPC’s proposed tender offer of $2.15 per share in cash, or $35 million, to acquire 100% of the outstanding shares of the company
	TM Capital analyzed the transaction and rendered a fairness opinion to the BioLok’s Board of Directors which was included in the company’s shareholder documents and public filings